HomeCompareIMGN vs PM

IMGN vs PM: Dividend Comparison 2026

IMGN yields 6.40% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PM wins by $19.0K in total portfolio value
10 years
IMGN
IMGN
● Live price
6.40%
Share price
$31.24
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$962.44
Full IMGN calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — IMGN vs PM

📍 PM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMGNPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMGN + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMGN pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMGN
Annual income on $10K today (after 15% tax)
$544.26/yr
After 10yr DRIP, annual income (after tax)
$818.07/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, PM beats the other by $1,300.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMGN + PM for your $10,000?

IMGN: 50%PM: 50%
100% PM50/50100% IMGN
Portfolio after 10yr
$40.1K
Annual income
$1,727.23/yr
Blended yield
4.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

IMGN
Analyst Ratings
6
Buy
15
Hold
1
Sell
Consensus: Hold
Price Target
$14.79
-52.6% upside vs current
Range: $6.36 — $22.00
Altman Z
18.1
Piotroski
3/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMGN buys
0
PM buys
0
No recent congressional trades found for IMGN or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMGNPM
Forward yield6.40%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$30.5K$49.6K
Annual income after 10y$962.44$2,492.02
Total dividends collected$8.1K$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$14.79$194.30

Year-by-year: IMGN vs PM ($10,000, DRIP)

YearIMGN PortfolioIMGN Income/yrPM PortfolioPM Income/yrGap
1← crossover$11,340$640.31$11,648$408.29$308.00PM
2$12,813$678.62$13,589$495.90$776.00PM
3$14,426$716.58$15,877$603.21$1.5KPM
4$16,190$754.03$18,580$734.88$2.4KPM
5$18,114$790.87$21,781$896.75$3.7KPM
6$20,209$826.97$25,578$1,096.12$5.4KPM
7$22,486$862.25$30,092$1,342.17$7.6KPM
8$24,957$896.64$35,470$1,646.46$10.5KPM
9$27,634$930.05$41,892$2,023.58$14.3KPM
10$30,531$962.44$49,578$2,492.02$19.0KPM

IMGN vs PM: Complete Analysis 2026

IMGNStock

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Full IMGN Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this IMGN vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMGN vs SCHDIMGN vs JEPIIMGN vs OIMGN vs KOIMGN vs MAINIMGN vs MOIMGN vs BTIIMGN vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.